CNATM ist einer von sieben Gewinnern der Clusters4Future Initiative des Bundesministeriums für Forschung, Technologie und Raumfahrt (BMFTR). Durch die multilateralen Kooperationen des CNATM entsteht ein Netzwerk, aus dem heraus neuartige nukleinsäure-basierte Wirkstoffe und Vakzine der nächsten Generation entwickelt werden sollen. Der Forschungsverbund besteht aus Wissenschaftlern*innen der federführenden Universitäten LMU München und der TUM, unter Beteiligung der Universitäten von Regensburg und Würzburg, dem Helmholtz-Zentrum München und 14 Unternehmen aus der Region um München.
Our Vision & Our Goals
CNATM is creating a network from which novel nucleic acid-based active substances and next-generation vaccines are to be developed. Nucleic acids have so far eluded drug development. The latest discoveries in the field of mRNA vaccines, but also in the field of nucleic acid therapies, now give rise to the hope that nucleic acids will soon be available as new ‘weapons’ in the fight against previously untreatable diseases. The ability to design nucleic acids in a highly specific and theoretically predictable way opens up completely new therapeutic approaches in medicine.
Scientists from very different disciplines are working together to achieve these goals. Chemistry researchers are developing new nucleic acid chemistry. Scientists from biochemistry and cell biology are researching sites and principles of action. Pharmacists are testing the active ingredients and polymer chemistry researchers are developing new delivery strategies. The physicians in the cluster are focussing their scientific efforts on the areas with the highest unmet medical needs. With the development of the first mRNA vaccine, Germany currently has a small lead in drug development, which is to be continuously expanded and further developed.
Projects in CNATM
Research and development projects
We are currently working on 11 projects, so-called Work Packages, in the fields of mono- and dinucleotides, oligonucleotides, delivery and formulation of nucleic acid therapeutics, as well as mRNA agents and other principles.
Measures to support innovation
We are working on a decentralised basis in a centrally managed joint project to implement our innovation-related measures.
News
Upcoming Events
Facts and figures
0
Spin-offs
0
Publications
0
Cooperations
